摘要
胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)是目前重要的降糖药物,具有多种代谢效应,在减轻体质量和2型糖尿病(diabetes mellitus type 2,T2DM)并发症治疗方面亦有重要影响。疗效方面,GLP-1RA存在一定比例应答不良,包括基线糖化血红蛋白、胰岛β细胞功能、GLP-1RA药物剂量、体质量指数、种族或可预测部分GLP-1RA血糖应答;耐受性方面,多数GLP-1RA耐受性与疗程呈负相关。T2DM的综合管理需以患者为中心进行个体化治疗。现总结GLP-1RA治疗T2DM血糖应答及耐受性相关基线特征,探寻使用GLP-1RA的适宜人群特征,旨在为临床用药提供一定参考。
Glucagon-like peptide-1 receptor agonist(GLP-1RA)is an important hypoglycemic agent,which has various metabolic effects.It plays an important role in reducing body mass and treating complications of diabetes mellitus type 2(T2DM).In terms of efficacy,GLP-1RA had a proportion of adverse responses,including baseline glycosylated hemoglobin,islet beta cell function,GLP-1RA drug dose,body mass index,ethnicity or predictable partial glycaemia response.In terms of tolerance,most GLP-1RA tolerance was negatively correlated with the course of treatment.The comprehensive management of T2DM requires patient-centered individualized treatment.This paper summarized the baseline characteristics related to glucose response and tolerance in the treatment of T2DM by GLP-1RA,and explored the appropriate population characteristics for GLP-1RA,in order to provide some reference for clinical medication.
作者
王晓琳
陆灏
WANG Xiaolin;LU Hao(Department of Endocrinology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)
出处
《世界临床药物》
CAS
2023年第2期186-192,共7页
World Clinical Drug
基金
国家自然科学基金(82074381、81874434)
长三角中医内分泌代谢病专科联盟[ZY(2021-2023)-0302]
上海市科委科研计划项目(21S21900700)
上海市临床重点专科(shslczdzk05401)
上海市中医临床重点实验室(20DZ2272200)
